Prednisolone in Pregnancy
Prednisolone can be used during pregnancy when needed to control active disease, but should be tapered to ≤5 mg/day whenever possible and withdrawn if feasible, as doses above this threshold significantly increase risks of gestational diabetes, preterm birth, maternal infections, and pregnancy-associated osteoporosis. 1
Safety Profile
Prednisolone is not teratogenic and does not increase the rate of major birth defects 1. This is reassuring for both planned and unplanned exposures. The drug undergoes minimal placental transfer compared to dexamethasone or betamethasone, making it preferable when maternal treatment (rather than fetal treatment) is the goal 2.
Dosing Strategy
Target Maintenance Dose
- Optimal dose: ≤5 mg/day - associated with low risk 1
- Taper to this level whenever disease activity permits
- Withdraw completely if clinically feasible
Higher Doses When Necessary
When disease control requires >5 mg/day, the decision must weigh:
- Risk of uncontrolled maternal disease (which itself harms pregnancy outcomes)
- Dose-dependent maternal-fetal complications
The 2025 EULAR guidelines explicitly state that higher dosages should be used only when the benefit outweighs maternal-fetal complication risks 1.
Dose-Related Risks
Maternal Complications (prolonged higher doses)
- Gestational diabetes
- Serious infections
- Pregnancy-associated osteoporosis
- Preterm birth 1
Quantified Preterm Birth Risk
Research demonstrates clear dose-response relationships:
- High cumulative dose trajectory: 4.77-fold increased PTB risk
- Medium cumulative dose: 1.81-fold increased PTB risk
- ≥10 mg/day after gestational day 139: 2.45-fold increased PTB rate 3
Fetal/Neonatal Outcomes
- Normal developmental milestones in exposed children 1
- No increased insulin resistance risk 1
- Conflicting data on infection rates in offspring 1
- Infants born to mothers on corticosteroids should be monitored for hypoadrenalism 4
Severe Refractory Disease
For life-threatening or organ-threatening maternal disease unresponsive to standard therapy:
- IV methylprednisolone pulses are preferred over high-dose oral prednisolone 1
- Consider pregnancy-compatible DMARDs or biologics
- IV immunoglobulin is an alternative 1
Pharmacokinetic Considerations
Prednisolone exhibits dose-dependent and concentration-dependent pharmacokinetics during pregnancy 5:
- Apparent oral clearance increases with dose (35.1 L/h at 5 mg → 64.3 L/h at 20 mg)
- Higher concentrations lead to increased percentage of unbound drug
- This may necessitate dose adjustments, though clinical monitoring of disease activity remains the primary guide
Lactation
Prednisolone is compatible with breastfeeding 5:
- Breast milk/plasma ratio: 0.02-0.03 for prednisolone
- Relative infant dose: 0.09-0.18%
- Minimal infant exposure via breast milk
Critical Caveats
Do not confuse with dexamethasone/betamethasone: These cross the placenta efficiently and are used for fetal lung maturation, not maternal disease control 2
Avoid abrupt discontinuation: After long-term therapy, taper gradually rather than stopping suddenly 4
Monitor for adrenal insufficiency: Patients on chronic corticosteroids may need stress-dose coverage for labor/delivery 2
Disease activity matters: The 2020 ACR guidelines emphasize that both active rheumatic disease AND continuous high-dose glucocorticoid treatment pose maternal-fetal harm 6. Uncontrolled disease may be more dangerous than appropriately dosed prednisolone.
Practical Algorithm
- Assess disease activity - Is prednisolone necessary?
- If yes, start/continue at lowest effective dose
- Target ≤5 mg/day maintenance as soon as disease permits
- If >5 mg/day required: Document justification, monitor closely for gestational diabetes, infections, preterm labor
- Consider steroid-sparing agents (pregnancy-compatible DMARDs/biologics) to facilitate prednisolone taper 6
- For severe refractory disease: Use IV methylprednisolone pulses rather than escalating oral doses 1